Evidence map›Paper›PMID 29404677›Full record

ArticleDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2019

[Marginal protection of retinal cells by bisperoxovanadium : Appropriate therapy in the model of retinal ischemia?]

M Glaser, M Palmhof, D Schulte, H Schmid, G Stute, H B Dick, S C Joachim

Abstract read
PubMed Publisher
In one paragraph

Article in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

M GlaserExperimental Eye Research Institute, Universitäts-Augenklinik, Ruhr-Universität Bochum, In der Schornau 23-25, 44892, Bochum, Deutschland.
M PalmhofExperimental Eye Research Institute, Universitäts-Augenklinik, Ruhr-Universität Bochum, In der Schornau 23-25, 44892, Bochum, Deutschland.
D SchulteExperimental Eye Research Institute, Universitäts-Augenklinik, Ruhr-Universität Bochum, In der Schornau 23-25, 44892, Bochum, Deutschland.
H SchmidExperimental Eye Research Institute, Universitäts-Augenklinik, Ruhr-Universität Bochum, In der Schornau 23-25, 44892, Bochum, Deutschland.
G StuteExperimental Eye Research Institute, Universitäts-Augenklinik, Ruhr-Universität Bochum, In der Schornau 23-25, 44892, Bochum, Deutschland.
H B DickExperimental Eye Research Institute, Universitäts-Augenklinik, Ruhr-Universität Bochum, In der Schornau 23-25, 44892, Bochum, Deutschland.
S C JoachimExperimental Eye Research Institute, Universitäts-Augenklinik, Ruhr-Universität Bochum, In der Schornau 23-25, 44892, Bochum, Deutschland. stephanie.joachim@rub.de.
Ruhr University Bochum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIschemic processes usually lead to the destruction of retinal cells and therefore play a key role in a multitude of eye diseases.

objectiveThe aim of this study was to investigate whether bisperoxovanadium has a potential neuroprotective effect in an ischemia/reperfusion animal model. MATERIAL AND

methodsInitially, ischemia was induced in one eye of an ischemia/reperfusion model and 3 days later, a 14-day medication-based treatment was initiated. Bisperoxovanadium was administered intraperitoneally every 3 days. Subsequently, the number of ganglion cells, the rate of apoptosis, amacrine cells, macroglia, microglia, and their activation state, as well as photoreceptors were determined by histological and immunohistochemical analyses.

resultsIn comparison to the control group, a significant retinal ganglion cell loss, a significant reduction of the inner layers as well as a decrease in photoreceptor and amacrine cell numbers could be determined in the ischemic eyes. In addition, there was an increase in the number of microglia in these animals. The rats treated with bisperoxovanadium did not exhibit a significant neuroprotective effect regarding the number of ganglion cells, the rate of apoptosis, macroglia, amacrine cells, or photoreceptors; however, a low structural degeneration of photoreceptors could be observed as an effect of the treatment. Additionally, fewer microglia and activated microglia were observed after bisperoxovanadium treatment.

conclusionBisperoxovanadium seems to have only a marginal neuroprotective effect on ischemic retinae. It needs to be examined whether earlier therapy onset, higher dose or different route of administration would significantly improve the results or whether this therapeutic approach is unsuitable.

Indexed as

Retinal DiseasesAnimalsDisease Models, AnimalIschemiaRatsRetinaRetinal Ganglion CellsVanadium CompoundsbisperoxovanadiumVanadium CompoundsAnimal modelGanglion cellsMicrogliaNeuroprotectionReperfusion

Identifiers

PMID29404677
OpenAlexW2790632196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.